Market Overview

Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts

Share:
Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts

Gene therapy is an emerging therapeutic area, and Axovant Gene Therapies Ltd (NASDAQ: AXGT) is an attractive play on the sector, according to Baird.

The Analyst

Brian Skorney upgraded Axovant from Neutral to Outperform and lowered the price target from $16 to $13.

The Thesis

Axovant's multiple opportunities to find an efficacious gene therapy make it an attractive investment ahead of data readouts scheduled for the fourth quarter, Skorney said in a Monday note. (See his track record here.) 

  • Axovant is due to release initial data from the first Type 2 GM1 gangliosidosis patient dosed with AXO-AAV-GM1 in the fourth quarter.
  • A data readout from AXO-AAV-GM2 is also expected in the fourth quarter.
  • Data on AXO-LENTI-PD is also due in the fourth quarter, which could provide additional clarity into its effect.

The analyst said the simplistic approach used by AXO-AAV-GM1 in gangliosidosis — usage of well-known AAV9 vector and the IV route of administration — improves the chances of its clinical success.

The company will likely pursue an abbreviated approval path, he said. 

The commercial uptake will likely be robust given the lack of approved therapies for patients with GM1 gangliosidosis, Skorney said. 

The second gene therapy program holds promise in the future despite the modest effect observed in the first patient doses in Axovant's ongoing AXO-AAV-GM2 trial, the analyst said.

The slight dosing change the company effected in the second patient may help enhance the early positive signal seen in the first patient, he said. 

If the results from the second dose cohort in the AXO-LENTI-PD study are positive, Baird expects AXGT shares to trade significantly higher given the valuation gap between Axovant and Voyager Therapeutics Inc (NASDAQ: VYGR), its key competitor.

Success in any of the company's three gene therapy programs would represent significant upside to today's value, Skorney said. 

Baird trimmed its price target to account for the likely dilution in shares that might be necessary to fund future development of the programs.

The Price Action

Axovant shares were higher by 3.79% at $6.57 at the close Monday. 

Related Links:

The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Latest Ratings for AXGT

DateFirmActionFromTo
Aug 2019UpgradesNeutralOutperform
Jun 2019Initiates Coverage OnOutperform
Apr 2019Initiates Coverage OnOutperform

View More Analyst Ratings for AXGT
View the Latest Analyst Ratings

Posted-In: Baird Brian SkorneyAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (VYGR + AXGT)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
XELMaintains60.0
SOMaintains54.0
SREMaintains141.0
EXCMaintains56.0
ESMaintains77.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at [email protected]

Morgan Stanley: Salesforce Shares Aren't Pricing In Strong Free Cash Flow Growth

Former Delta Air Lines Safety Chief Sworn In To Lead FAA